X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the collaboration, companies will combine proprietary technologies to formulate an oral semaglutide (GLP-1 receptor agonist) with enhanced bioavailability, using a novel lipid technology to provide a more convenient treatment for patients with diabetes and obesity.
Lead Product(s): Semaglutide
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: TRx BIOSCIENCES
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 12, 2024
Details:
Ogluo® is a ready-to-use, ambiently stored, preparation of glucagon that has been specifically designed for patients living with diabetes with severe hypoglycaemia.
Lead Product(s): Glucagon
Therapeutic Area: Endocrinology Product Name: Ogluo
Highest Development Status: ApprovedProduct Type: Peptide
Recipient: Tetris Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 12, 2022
Details:
AT247 (ultra rapid acting prandial insulin aspart) has the potential to significantly improve blood glucose control when delivered via insulin pump and is an important step in enabling the development of a fully closed loop/artificial pancreas system for people with diabetes.
Lead Product(s): Ultra Rapid Acting Prandial Insulin Aspart
Therapeutic Area: Endocrinology Product Name: AT247
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2022
Details:
Humira approved as 50 mg/mL adalimumab product comprising citrate as formulation ingredient. An product was subsequently launched by AbbVie with high adalimumab concentration in absence of citrate, providing greater patient convenience due to the lower injection volumes.
Lead Product(s): Adalimumab
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 09, 2022
Details:
Under the terms of the proposed acquisition, Arecor Therapeutics has agreed to acquire Tetris Pharma and will continue to commercialize Ogluo in the UK and EEA. Gvoke® (US) /Ogluo® (EU), the first prescription, ready-to-use, pre-mixed, pre-measured glucagon injection.
Lead Product(s): Glucagon
Therapeutic Area: Endocrinology Product Name: Ogluo
Highest Development Status: ApprovedProduct Type: Peptide
Recipient: Tetris Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 01, 2022
Details:
Data from Phase I clinical trial of AT278 (Ultra-Concentrated Rapid Acting Insulin Aspart), showed that it exhibited an accelerated PK and PD profile when compared to NovoRapid®, a gold standard prandial insulin treatment, despite a 5-fold increase in concentration.
Lead Product(s): Ultra-Concentrated Rapid Acting Insulin Aspart
Therapeutic Area: Endocrinology Product Name: AT278
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2022
Details:
PK/PD profile for AT278 was accelerated compared with NovoRapid. Following dosing, AT278 showed faster onset of insulin exposure compared with NovoRapid, demonstrated by an earlier onset of appearance, also showed rapid onset of glucose-lowering effect compared with NovoRapid.
Lead Product(s): Ultra-Concentrated Rapid Acting Insulin Aspart
Therapeutic Area: Endocrinology Product Name: AT278
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2022
Details:
AT278, is an ultra-concentrated novel formulation of insulin, that has been designed to significantly accelerate insulin absorption post injection to enable more effective and convenient management of blood glucose levels in people with high daily insulin requirements.
Lead Product(s): Ultra-Concentrated Rapid Acting Insulin Aspart
Therapeutic Area: Endocrinology Product Name: AT278
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2022
Details:
AT247 is an ultra-rapid insulin that aims to accelerate insulin absorption, post injection, to enable more effective management of blood glucose levels for people living with diabetes, particularly around difficult to manage mealtimes.
Lead Product(s): Insulin aspart
Therapeutic Area: Endocrinology Product Name: AT247
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2022
Details:
First patient dosed in potential game-changing diabetes combination therapy of AT247 (Ultra-rapid Insulin), exhibited an earlier insulin appearance, exposure, and offset, with corresponding enhanced early glucose-lowering effect compared with NovoRapid® and Fiasp®.
Lead Product(s): Ultra-rapid Acting insulin Aspart,Rapid Acting Insulin Aspart,Fast Acting Insulin Aspart
Therapeutic Area: Endocrinology Product Name: AT247
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
